A Study to Assess New Formulations of TEV-56286

Phase 1 Completed 47 enrolled Teva Branded Pharmaceutical Products R&D, Inc.

RandomizedCrossoverOpen-labelOther

Summary

The primary objective of the study is to assess the relative bioavailability of TEV-56286 test formulations compared to TEV-56286 reference product in healthy adult participants. The secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned duration for each participant is approximately 70 days which includes a 45 day screening period.

Timeline

Start: 2025-03-10
Primary completion: 2025-05-22
Completion: 2025-06-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TEV-56286	Unknown	—	Oral

Indications

No indication recorded.